Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

5/20/2022
BreakingGlaucomaLaserRegulation
Belkin’s Automated, Contactless Laser for Glaucoma Gains CE Marking
Belkin’s Automated, Contactless Laser for Glaucoma Gains CE Marking

Israel’s Belkin Vision announced May 16 that its Eagle automated laser treatment for glaucoma received CE marking. The Eagle is the first contactless laser for glaucoma. Controlled rollout of the s...

5/20/2022
BreakingRegulationRetina
UK is First in Europe to Approve Teva’s Lucentis Biosimilar Ongavia
UK is First in Europe to Approve Teva’s Lucentis Biosimilar Ongavia

Israel’s Teva Pharmaceutical Industries announced May 17 that the UK’s Medicines & Healthcare Regulatory Agency (MHRA) had granted marketing approval to Ongavia, a Lucentis (ranibizumab) biosimilar...

5/20/2022
BreakingDealsDiagnostic
Visionix to Distribute Righton Products in Europe, the Americas, and Select Asia Pacific Countries
Visionix to Distribute Righton Products in Europe, the Americas, and Select Asia Pacific Countries

Visionix, formerly Luneau Technology, and Japan’s Right MFG announced May 16 that they had entered a long-term strategic partnership agreement. Financial terms of the deal were not disclosed. Visio...

5/20/2022
BreakingDealsGlaucomaPharma
Skye to Acquire Emerald in Stock Deal, List on Canadian Securities Exchange
Skye to Acquire Emerald in Stock Deal, List on Canadian Securities Exchange

Cannabis companies Skye Bioscience and Emerald Health Therapeutics announced May 12 that they had signed a deal for Skye to acquire all shares of Emerald in a share-for-share transaction that inclu...

5/20/2022
BreakingClinical TrialCornealDry Eye
Brim Partners with Ora for Phase III Trial of Dry Eye Candidate
Brim Partners with Ora for Phase III Trial of Dry Eye Candidate

Brim Biotechnology, of Taiwan, announced May 17 that it had partnered with ophthalmic research company Ora on a Phase III clinical trial, set to begin in Q4-2022, for Brim’s lead drug candidate, BR...

5/20/2022
BreakingCataractClinical TrialPharma
Formosa, AimMax See Positive Results in Phase III Trial of Post-cataract Inflammation, Pain Candidate
Formosa, AimMax See Positive Results in Phase III Trial of Post-cataract Inflammation, Pain Candidate

Formosa Pharmaceuticals and AimMax Therapeutics reported positive results May 12 from the first of two pivotal Phase III studies of APP13007, a novel ophthalmic nanosuspension of the corticosteroid...

5/20/2022
BreakingCataractGlaucomaIndustryPharma
Visiox Pharma Appoints Ryan S. Bleeks as Chief Executive Officer
Visiox Pharma Appoints Ryan S. Bleeks as Chief Executive Officer

Visiox Pharma, which is advancing new formulations of well-known ophthalmic compounds, announced May 17 that it had appointed Ryan S. Bleeks as chief executive officer. Previously, Bleeks was vice ...

5/13/2022
BreakingDealsPresbyopia
Zhaoke Licenses Visus’ Presbyopia Drop Candidates for Greater China, South Korea, Select Southeast Asian Markets
Zhaoke Licenses Visus’ Presbyopia Drop Candidates for Greater China, South Korea, Select Southeast Asian Markets

Visus Therapeutics announced May 11 that Hong Kong’s Zhaoke Ophthalmology had signed an exclusive licensing agreement for the development and commercialization of presbyopia drop candidates Brimoch...

5/13/2022
BreakingCataractDry EyeGlaucomaIOLRevenue
Q1-2022 Ophthalmic Revenue Roundup for Alcon, Glaukos, Aerie, Harrow, and Eight Others
Q1-2022 Ophthalmic Revenue Roundup for Alcon, Glaukos, Aerie, Harrow, and Eight Others

Alcon reported May 10 that its Q1-2022 sales were $2.2 billion, an increase of 14 percent over $1.9 billion in Q1-2021. Surgical net sales increased 17 percent and totaled $1.3 billion, consisting ...

5/13/2022
BreakingIndia
Orbis Opens 18 Solar-Powered ‘Green Vision Centers’ in India
Orbis Opens 18 Solar-Powered ‘Green Vision Centers’ in India

The non-profit group Orbis International announced April 22 the recent opening of 18 so-called Green Vision Centers, aiming to bring quality eye care to children in rural communities in India’s Ker...

5/13/2022
BreakingClinical TrialRetina
Oxurion Drops DME Candidate After Disappointing Phase II Results
Oxurion Drops DME Candidate After Disappointing Phase II Results

Belgium’s Oxurion reported May 9 that it would not advance THR-687, a pan-RGD integrin inhibitor, into the second part of its Phase II trial in diabetic macular edema (DME), after disappointing top...

5/13/2022
BreakingDealsRetina
EyePoint Expands Licensing Deal with Betta for Wet AMD Candidate in Greater China
EyePoint Expands Licensing Deal with Betta for Wet AMD Candidate in Greater China

EyePoint Pharmaceuticals, maker of Yutiq and Dexycu, announced May 4 that it had expanded its licensing agreement with China’s Betta Pharmaceuticals to develop and commercialize EYP-1901 for wet ag...

Past News Stories

5/13/2022
BreakingCataractIOLSurgical
Switzerland’s SAV-IOL Unveils its Instant Focus EDOF IOL Technology
Switzerland’s SAV-IOL Unveils its Instant Focus EDOF IOL Technology

Swiss company SAV-IOL unveiled on May 5 its Instant Focus EDOF (extended depth of focus) optical technology for its intraocular lenses (IOLs). The company says that, unlike other EDOF technologies,...

5/13/2022
BreakingGlaucomaLaser
Zeiss Offers New SLT Add-On for Visulas Green Laser
Zeiss Offers New SLT Add-On for Visulas Green Laser

Carl Zeiss Meditec announced May 4 that it now offers a selective laser trabeculoplasty (SLT) add-on to its Visulas green laser, part of its integrated Glaucoma Workflow. SLT is based on the photot...

5/13/2022
BreakingDealsRetina
Catalyst Regains Rights to C3 Inhibitor for Dry AMD
Catalyst Regains Rights to C3 Inhibitor for Dry AMD

Catalyst Biosciences reported May 9 in its Q1-2022 earnings summary that it had regained the rights to CB 2782-PEG, a complement C3 inhibitor, from Biogen for the potential treatment of dry age-rel...

5/13/2022
BreakingClinical TrialRetina
ABVC BioPharma Revamps Manufacturing of Vitargus Ahead of Clinical Trials
ABVC BioPharma Revamps Manufacturing of Vitargus Ahead of Clinical Trials

ABVC BioPharma, formerly known as American BriVision, announced May 5 a new manufacturing process for its vitreous substitute candidate Vitargus, in preparation for upcoming clinical studies. ABVC ...

5/13/2022
BreakingRegulationRetina
Belite Bio Earns FDA Fast Track Nod for Oral Stargardt Candidate
Belite Bio Earns FDA Fast Track Nod for Oral Stargardt Candidate

Belite Bio announced May 3 that LBS-008 (tinlarebant), its oral treatment candidate for Stargardt, had been granted fast track designation by the US FDA. LBS-008 has already been granted rare pedia...

5/13/2022
BreakingIndustryRetina
Vedere Bio II Appoints Anna-Maria Demetriades, MD, PhD, as Chief Medical Officer
Vedere Bio II Appoints Anna-Maria Demetriades, MD, PhD, as Chief Medical Officer

Vedere Bio II announced April 26 that it had appointed Anna-Maria Demetriades, MD, PhD, as chief medical officer. The Cambridge, Massachusetts, company was founded by the leadership and research te...

5/19/2022
Press Release
Glaucoma Pharma Market Sees Growing Tug-of-War Between Rising Treatment, Lower Prices
Glaucoma Pharma Market Sees Growing Tug-of-War Between Rising Treatment, Lower Prices

Generic competitors to previously unchallenged brand name products in the US are keeping the lid on revenue from glaucoma pharmaceuticals. Teva Pharmaceutical Industries launched the first US FDA-a...

5/6/2022
BreakingFunding
Bausch + Lomb Sets IPO Share Price at $18, Begins Trading on NYSE
Bausch + Lomb Sets IPO Share Price at $18, Begins Trading on NYSE

Bausch + Lomb announced May 5 that it had priced its initial public offering at $18 per share, below its targeted $21 to $24 range reported in an SEC filing on April 28. The stock began trading May...

5/6/2022
BreakingDry EyeLaserPresbyopiaRefractiveRetinaRevenue
Q1-2022 Ophthalmic Revenue Roundup for Regeneron, Horizon, Allergan, STAAR, Lumibird
Q1-2022 Ophthalmic Revenue Roundup for Regeneron, Horizon, Allergan, STAAR, Lumibird

Regeneron, of Tarrytown, New York, reported May 4 that its Q1-2022 US revenue for Eylea was $1.52 billion, a 13 percent increase over $1.35 billion in Q1-2021. Regeneron’s collaboration revenue rel...

5/6/2022
BreakingCorneal
CorneaGen Introduces Preloaded Graft Insertion Device for DSEK
CorneaGen Introduces Preloaded Graft Insertion Device for DSEK

CorneaGen announced April 28 the release of its EndoSerter-PL, a new US FDA approved, single-use graft insertion device preloaded with processed tissue to help streamline Descemet’s stripping endot...

5/6/2022
BreakingIndustry
J&J Vision Appoints Peter Menziuso as Company Group Chairman Over Surgical, Vision Care Units
J&J Vision Appoints Peter Menziuso as Company Group Chairman Over Surgical, Vision Care Units

Johnson & Johnson Vision announced May 3 that it had appointed Peter Menziuso as company group chairman. Menziuso will oversee the two units that make up J&J Vision—Johnson & Johnson Surgical Visio...

5/6/2022
BreakingClinical TrialRegulation
Ocuphire Concludes Pediatric Safety Trial for Nyxol, Plans NDA Filing for Reversal of Mydriasis in Late 2022
Ocuphire Concludes Pediatric Safety Trial for Nyxol, Plans NDA Filing for Reversal of Mydriasis in Late 2022

Ocuphire Pharma announced April 28 that it saw positive results in the MIRA-4 pediatric safety trial of Nyxol for the reversal of pharmacologically induced mydriasis (dilation of pupil). Nyxol’s ef...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more